| US 7,569,364 B2 | ||
| Anti-NGF antibodies and methods using same | ||
| Arnon Rosenthal, Woodside, Calif. (US); David L. Shelton, Oakland, Calif. (US); and Patricia A. Walicke, Brisbane, Calif. (US) | ||
| Assigned to Pfizer Inc., New York, N.Y. (US) | ||
| Filed on Apr. 11, 2005, as Appl. No. 11/104,248. | ||
| Application 11/104248 is a continuation in part of application No. 10/745775, filed on Dec. 24, 2003. | ||
| Claims priority of provisional application 60/510006, filed on Oct. 08, 2003. | ||
| Claims priority of provisional application 60/443522, filed on Jan. 28, 2003. | ||
| Claims priority of provisional application 60/436905, filed on Dec. 24, 2002. | ||
| Prior Publication US 2008/0182978 A1, Jul. 31, 2008 | ||
| Int. Cl. A61K 39/395 (2006.01); A61P 19/02 (2006.01); A61P 29/02 (2006.01); C07K 16/22 (2006.01) | ||
| U.S. Cl. 435—70.2 [424/133.1; 424/145.1; 530/388.1; 530/388.24] | 16 Claims |
| 1. A method for treating osteoarthritis pain in an individual comprising administering an effective amount of an anti-NGF
antagonist antibody, wherein said antibody comprises a heavy chain variable region comprising:
(a) the CDR1 region shown in SEQ ID NO: 3;
(b) the CDR2 region shown in SEQ ID NO: 4; and
(c) the CDR3 region shown in SEQ ID NO: 5; and wherein said antibody further comprises a light chain variable region comprising:
(d) the CDR1 region shown in SEQ ID NO: 6;
(e) the CDR2 region shown in SEQ ID NO: 7; and
(f) the CDR3 region shown in SEQ ID NO: 8.
|